Last reviewed · How we verify

NCT06264466

Safety and Efficacy of a Novel Flexible Bipolar in POEM

Status unknown NA Last updated 20 February 2024
What this trial tests

NA trial testing POEM with Speedboat Ultraslim in Esophageal Achalasia in 73 participants. Status unknown.

Timeline
1 December 2023
Primary endpoint
1 December 2024
15 January 2025

Quick facts

Lead sponsorInstituto Ecuatoriano de Enfermedades Digestivas
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment73
Start date1 December 2023
Primary completion1 December 2024
Estimated completion15 January 2025
Sites1 location across Ecuador

Drugs / interventions tested

Conditions studied

Sponsor

Instituto Ecuatoriano de Enfermedades Digestivas — full company profile →

Who can join

Adults 18 to 90, any sex, with Esophageal Achalasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Per-oral endoscopic myotomy (POEM) is a minimally invasive therapy for achalasia. The procedure has demonstrated high technical and clinical success with lower adverse events. Different types of knives have been used for cutting and coagulation during the procedure; however, exchanging accessories is sometimes needed to perform all the stages of POEM. To overcome this disadvantage, the investigators aim to evaluate a single device that integrates in its tip bipolar radiofrequency and microwave, the Speedboat Ultraslim (Creo Medical, UK) for cutting and coagulation during POEM procedure. Some of the promise's advantages derived from its use are: (1) less inflammation, (2) clear differentiation between layers, (3) the use of a single device for the procedure. This single-center, prospective, interventional study will include patients with achalasia submitted to POEM procedure, with or without fundoplication (POEM-F). All stages (mucosal incision, submucosal tunneling, myotomy) of POEM will be performed using the Speedboat ultraslim flexible catheter. Technical and clinical success, along with safety will be the primary endpoints; while, post-procedure reflux symptoms and quality of life will be assessed as secondary outcomes with reflux severity index (RSI) and the Northwestern Esophageal Quality of Life (NEQOL), respectively.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Esophageal Achalasia

Currently open trials in the same condition.

Other Instituto Ecuatoriano de Enfermedades Digestivas trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06264466.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing